As the pathology profession faces an ageing workforce, widespread burnout, and increasing clinical demand, the integration of automation through platforms like NGX 124 can deliver tangible and immediate benefits.

1. Alleviating Workforce Pressures
   With 47% of UK pathologists aged 50 or over and nearly a quarter bringing forward their retirement, the pathology workforce is under strain. NGX 124 supports workforce sustainability by:

• • Reducing reliance on senior laboratory staff through intuitive, technician-level operation.
  • Freeing up biomedical scientists (BMSs) for complex interpretation and decision-making tasks by automating repetitive, manual workflows.

2. Minimising Unpaid Overtime and Burnout
   The census highlights that 60% of UK consultants work beyond contracted hours, largely due to clinical and administrative overload. NGX 124 helps mitigate this by:

• • Automating sample-to-result workflows, reducing time spent on manual processing and quality assurance.
  • Streamlining diagnostic throughput with ultra-fast qPCR capabilities and rapid sample cycling.

This improves productivity without placing additional strain on overstretched staff, helping to counteract the burnout and work-life imbalance cited as top reasons for early retirement.

3. Enhancing Flexibility and Retention
   With 40% of pathologists planning to reduce working hours, labs must adapt to new working patterns. NGX 124 supports this shift by:

• • Allowing flexible deployment with its compact footprint (0.7m²) and rapid setup time (<15 mins).
  • Enabling a decentralised testing deployment model, which can reduce central lab bottlenecks and accommodate remote or part-time staffing.

4. Addressing Diagnostic Backlogs Efficiently
   As clinical demand grows and waiting lists lengthen, the NGX 124:

• • Delivers high-throughput testing (1–92 samples per run, plus 4 controls).
  • Minimises hands-on time through features like automated plate sealing, on-the-fly fluorescence capture, and Pathtube® sample handling.

This supports faster turnaround times for results, helping labs tackle backlogs without increasing staff workload.

5. Future-Proofing Services
   The College’s warning of unsustainable workloads and “worrying delays to diagnosis” underscores the need for long-term investment.
   The NGX 124 contributes by:

• • Empowering labs to scale operations without proportional increases in staffing costs.
  • Allowing continued use of existing LDTs and CE-IVD assays, preserving test familiarity while enhancing efficiency.
  • Using AI to look for test result patterns and so providing early prediction of a future pandemic

As Peter Johnston of the Royal College of Pathologists noted, “Investment in pathology is vital to meet growing clinical demand.”  The NGX 124 platform directly aligns with this call, offering a scalable, cost-effective, and practical solution to help safeguard the sustainability of diagnostic services amid workforce attrition and rising pressures. It is not merely a tool for testing, it is an investment in the future resilience of the UK’s pathology system.